David Roe is a growth-driven healthcare executive with more than 20 years of experience growing firms in the private, publicly traded, and not-for-profit sectors across multiple services, creating partnerships with C-suites, operations, and clinical areas to address and resolve strains presented by the continually evolving healthcare landscape.

Mr. Weatherwax has a 25-year career in healthcare services with roles including corporate finance and operational management. He led the corporate development efforts at a behavioral health provider and co-founded a boutique healthcare private equity company and held executive roles for healthcare staffing and home healthcare providers.

A founder of PAS, one of the largest companies offering in-home Ambulatory Video-EEG services (acquired by CortiCare), and a seasoned sales management professional, Carl oversees the US sales team, with a focus on serving the customer and providing the best solutions to meet their requirements.

Previous Operations Manager for Nuehealth, patient relationship SAAS connecting patients with providers. Previous customer service manager at Alpine Biomed, neuro-based diagnostic products.

Over 25 years of experience in Finance, Operations, and Business Development. Previously managed several start-up operations in the U.S. and overseas and also owned or served as CFO / Controller for several companies in the service industry.

Former VP of Marketing for Compumedics USA, Inc. with over 30 years’ experience in product management, marketing, sales, and sales and marketing management in cardiopulmonary and neurology focused capital equipment and services businesses, including management of a sleep study services business.

Former Senior Manager at several neurodiagnostic services companies, with experience managing a diverse and remotely located operations team.  He has previously held served as the Infection Control Officer and successfully navigated a team to achieve accreditation by The Joint Commission.

Dr. Anderson obtained both his M.D. and Ph.D. at the University of Nebraska Medical Center. He completed his fellowship in clinical neurophysiology with a sub specialization in epilepsy at Emory University. He is widely licensed and credentialed and currently practices telemedicine in 25 states and over 80 hospitals.

With 20 years’ experience in neurodiagnostics, she is the former Chief Technologist at Massachusetts General Hospital.  She serves as Adjunct Faculty in the Neurodiagnostic Technology program at Labouré College and is the current chairperson of the Research Committee for ASET- the Neurodiagnostic Society.

David Roe is a growth-driven healthcare executive with more than 20 years of experience growing firms in the private, publicly traded, and not-for-profit sectors across multiple services, creating partnerships with C-suites, operations, and clinical areas to address and resolve strains presented by the continually evolving healthcare landscape.

Principal with 1315 Capital. Ian Li joined 1315 Capital in 2015 and is a Principal on the investment team. Prior to investing, Ian was a healthcare management and strategy consultant at Capgemini Consulting. Ian has worked with commercial executives from top pharmaceutical companies on implementing large scale strategic initiatives, with projects spanning market access, product launch, healthcare reform readiness, and engagement of integrated health network (IHN) customers. Prior to consulting, Ian also had experience working at Stryker Orthopaedics in the quality engineering department. He currently serves on the board of 3B Scientific, CortiCare, and miraDry. Ian also serves as Co-Chair of the Duke University Philadelphia Alumni Board, is on the board of Philadelphia’s Magic Gardens, and is on the leadership team of Out Investors. Ian received a BSE in Biomedical Engineering from Duke University, with a minor in Economics.

Scott Cramer is an Operating Team Member at 1315 Capital, a healthcare expansion and growth equity firm. Scott has over 35 years’ experience and is a proven and focused medical device, diagnostics and consumer products CEO. He has significant experience driving change by instilling a culture of high performance and implementing growth strategies as well as operational improvement initiatives, resulting in a track-record of successful exits. Most recently Scott was CEO of DNA Diagnostics Center which was a world leader in paternity and relationship testing. The company was acquired by Eurofins in August 2021. Prior to DDC, Scott served as the President and CEO of Accriva Diagnostics. The Company had a portfolio of diagnostics devices for coagulation and platelet function testing. The Company closed all NJ operations and moved to a new facility in San Diego. Accriva was successfully sold to Werfen Life in January 2017. Previously Scott was President and CEO of Novasys Medical. The Company was focused on treating women with stress incontinence. Novasys was sold to Roper Industries in Dec. 2012. Prior to joining Novasys, he served as President and CEO of Bacchus Vascular, a company focused on peripheral vascular disease, where he successfully negotiated the sale of the Company to Covidien plc in March 2009. Prior to his CEO roles Scott was the Senior Vice President of U.S. Sales and Services for VNUS Medical, which was also acquired by Covidien plc. Scott joined VNUS in 2000. From 1997 through 2000, Scott was Vice President Sales at EndoSonics, a cardiovascular device company which later became Volcano Corporation. From 1996 to 1997, he served as NSM at Cardiometrics, which was acquired by Endosonics Corporation. From 1990 to 1995, Scott held several positions at Baxter Healthcare Corporation’s cardiovascular division. Scott currently serves on the board of Biocoat, CortiCare, and Harmac Medical Products. Scott served as Executive Chairman of NeuWave Medical, and has also previously served on the BOD of DDC, Accriva, Veran Medical (acquired by Olympus), Vascular Insights (acquired by Merit Medical), AccuVein, Novasys and Bacchus. He holds a B.S. degree in Finance from Philadelphia University.